TBRIF Stock Chart & Stats
$0.04
<$0.01(2.40%)
At close: 4:00 PM EDT
$0.04
<$0.01(2.40%)
Day’s Range― - ―
52-Week Range$0.03 - $0.09
Previous CloseN/A
Volume21.00K
Average Volume (3M)4.36K
Market Cap
$2.18M
Enterprise Value$3.38
Total Cash (Recent Filing)$25.13K
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding61,246,628
10 Day Avg. Volume395
30 Day Avg. Volume4,359
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.51
Price to Sales (P/S)48.92
P/FCF Ratio-26.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Gross MarginSustained revenue recovery and a materially improved gross margin indicate improving product-market fit and better unit economics. Higher gross margin supports operating leverage as sales scale, offering a durable path to margin expansion if revenue growth continues without proportional cost increases.
Improving Cash Burn TrendNarrowing operating cash deficits and positive free cash flow growth on a TTM basis reflect disciplined cost control and operational improvement. A durable reduction in cash burn lowers near-term financing needs and increases runway, improving chances of reaching sustainable cash generation.
Low Absolute Debt BurdenMinimal absolute debt reduces refinancing pressure and interest expense risk, preserving financial flexibility during a growth phase. For a small, loss-making med-tech developer, low leverage is a structural advantage that eases the path to obtaining additional capital when needed.
Bears Say
Large Net Losses & Negative EquityCumulative losses have eroded the capital base, leaving shareholders' equity negative. This structural weakness constrains financing options, increases reliance on dilutive equity or external funding, and raises long-term solvency and governance risks absent a sustained return to profitability.
Ongoing Negative Operating Cash FlowPersistent negative operating and free cash flow means the business still consumes cash to operate. Even with improvements, lack of sustainable positive cash generation heightens refinancing risk and can force strategic compromises or slowed investment in product development and commercial expansion.
Small Revenue Base Vs Cost StructureAlthough growth is strong percentage-wise, absolute revenue remains small relative to reported net losses and operating costs. This scale mismatch implies structural execution risk: the company must sustain large revenue increases to absorb fixed costs and reach break-even, a multi-period challenge.
Therma Bright News
TBRIF FAQ
What was Therma Bright’s price range in the past 12 months?
Therma Bright lowest stock price was $0.03 and its highest was $0.09 in the past 12 months.
What is Therma Bright’s market cap?
Therma Bright’s market cap is $2.18M.
When is Therma Bright’s upcoming earnings report date?
Therma Bright’s upcoming earnings report date is Dec 01, 2026 which is in 123 days.
How were Therma Bright’s earnings last quarter?
Therma Bright released its earnings results on Jun 25, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Therma Bright overvalued?
According to Wall Street analysts Therma Bright’s price is currently Overvalued.
Does Therma Bright pay dividends?
Therma Bright does not currently pay dividends.
What is Therma Bright’s EPS estimate?
Therma Bright’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Therma Bright have?
Therma Bright has 61,246,628 shares outstanding.
What happened to Therma Bright’s price movement after its last earnings report?
Therma Bright reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Therma Bright?
Currently, no hedge funds are holding shares in TBRIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Therma Bright
Established in Toronto, Canada, in 2001 as The Jenex Corporation before rebranding to Therma Bright Inc. in February 2018, Therma Bright Inc. specializes in creating and distributing various medical and consumer health products. Their diverse offerings include rapid COVID-19 diagnostic tests like AcuVid, which screens for both antigens and antibodies. For pain relief, they provide devices such as Benepod, a hot and cold contrast therapy system designed to manage discomfort without medication. The company also addresses circulatory issues with Venowave, a medical compression pump aimed at mitigating symptoms associated with poor circulation. Furthermore, Therma Bright caters to the cosmeceutical industry with products like InterceptCS, a cold sore prevention system utilizing safe, controlled topical heat, and TherOZap, a thermal device that alleviates the pain, itching, and inflammation from insect bites and stings by reducing the inflammatory response. Their clientele spans both individual consumers and healthcare practitioners.
Technical Analysis
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―